Impact of CDK4/6 inhibitors on health-related quality of life outcomes in patients with metastatic breast cancer: A systematic review and meta-analysis
OncologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Journal of managed care & specialty pharmacy
- Publicado em
- 1 dez 2025
- Citações
- 2
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Impact of CDK4/6 inhibitors on health-related quality of life outcomes in patients with metastatic breast cancer: A systematic review and meta-analysis
Takako Kiener, Kevin H Li, Erin Chiang, Quang A Le
Descritores MeSH
- Antineoplastic Agents
- Quality of Life
- Breast Neoplasms
- Protein Kinase Inhibitors
- Cyclin-Dependent Kinase 4
- Cyclin-Dependent Kinase 6
- Pyridines
- Randomized Controlled Trials as Topic
- Purines
- Benzimidazoles
Veja também
Estudos relacionados
- Hematological toxicity of cyclin-dependent kinase 4/6 inhibitors in patients with breast cancer: a network meta-analysis and pharmacovigilance study
- CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials
- Efficacy and safety of treatments in HR+/HER2- advanced breast cancer after CDK4/6 inhibitor progression: a network meta-analysis and scoping review
- Risk of QTc prolongation, and major cardiovascular adverse events associated with CDK4/6 inhibitors in hormone receptor-positive HER2-negative breast cancer - A systematic review and meta-analysis
- Inibição CDK4/6 na Gestão do Câncer de Mama Metastático HR+/HER2+: Revisão Sistemática e Meta-análise